Efflux pumps and nosocomial antibiotic resistance: A primer for hospital epidemiologists

Clinical Infectious Diseases

Volumn 40, Issue 12, 2005, Pages 1811-1817

  Hooper, David C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CETRIMIDE; CHLORAMPHENICOL; CHLORHEXIDINE; CIPROFLOXACIN; DISINFECTANT AGENT; ERYTHROMYCIN; FUSIDIC ACID; GLYCOPROTEIN P; IMIPENEM; MACROLIDE; MOXIFLOXACIN; NALIDIXIC ACID; NEOMYCIN; NORFLOXACIN; NOVOBIOCIN; PENICILLIN DERIVATIVE; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPARFLOXACIN; STREPTOGRAMIN DERIVATIVE; TETRACYCLINE DERIVATIVE; TRICLOSAN; TRIMETHOPRIM; VIRGINIAMYCIN;

ANTIBIOTIC RESISTANCE; DIFFUSION; GENE CONTROL; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL CARE; HOSPITAL INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PUMP; REVIEW; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; MEMBRANE TRANSPORT PROTEINS;

EID: 20444376938     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/430381     Document Type: Review

References (65)

1. Köhler T, Pechère JC, Plésiat P. Bacterial antibiotic efflux systems of medical importance. Cell Mol Life Sci 1999; 56:771-8.
2. Poole K. Efflux-mediated resistance to fluoroquinolonesin gram-negative bacteria. Antimicrob Agents Chemother 2000; 44:2233-41.
3. Poole K. Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria. Antimicrob Agents Chemother 2000; 44: 2595-9.
4. Putman M, Van Veen HW, Konings WN. Molecular properties of bacterial multidrug transporters. Microbiol Mol Biol Rev 2000; 64:672-93.
5. Nikaido H, Thanassi DG. Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples. Antimicrob Agents Chemother 1993; 37:1393-9.
6. Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev 2003; 67:593-656.
7. Cohen SP, Hooper DC, Wolfson JS, Souza KS, McMurry LM, Levy SB. Endogenous active efflux of norfloxacin in susceptible Escherichia coli. Antimicrob Agents Chemother 1988;32:1187-91.
8. Fung-Tomc JC, Gradelski E, Huczko E, Dougherty TJ, Kessler RE, Bonner DP. Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins. Antimicrob Agents Chemother 1996; 40:1289-93.
9. Roberts MC. Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution. FEMS Microbiol Rev 1996; 19:1-24.
10. Goldstein FW, Kitzis MD, Acar JF. N,N-dimethylglycyl-amido derivative of minocycline and 6-demethyl-6-desoxytetracycline, two new glycylcyclines highly effective against tetracycline-resistant gram-positive cocci. Antimicrob Agents Chemother 1994; 38:2218-20.
11. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001; 65:232-60.
12. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002; 34:482-92.
13. Farrell DJ, Morrissey I, Bakker S, Felmingham D. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumonias and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J Antimicrob Chemother 2002; 50:39-47.
14. Leclercq R, Courvalin P. Resistance to macrolides and related antibiotics in Streptococcus pneumonias. Antimicrob Agents Chemother 2002; 46: 2727-34.
15. Matsuoka M, Inoue M, Endo Y, Nakajima Y. Characteristic expression of three genes, msr(A), mpft(C) and erm(Y), that confer resistance to macrolide antibiotics on Staphylococcus aureus. FEMS Microbiol Lett 2003; 220:287-93.
16. Rosenberg EY, Bertenthal D, Milles ML, Bertrand KP, Nikaido H. Bile salts and fatty acids induce the expression of Escherichia coli AcrAB multidrug efflux pump through their interaction with Rob regulatory protein. Mol Microbiol 2003; 48:1609-19.
17. Saier MH, Jr, Paulsen IT, Sliwinski MK, Pao SS, Skurray RA, Nikaido H. Evolutionary origins of multidrug and drug-specific efflux pumps in bacteria. FASEB J 1998; 12:265-74.
18. Lomovskaya O, Lee A, Hoshino K, et al. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43:1340-6.
19. Livermore DM. Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother 2003; 51(Suppl 2):9-16.
20. Yu EW, McDermott G, Zgurskaya HI, Nikaido H, Koshland DE, Jr. Structural basis of multiple drug-binding capacity of the AcrB multidrug efflux pump. Science 2003; 300:976-80.
21. Paulsen IT, Brown MH, Skurray RA. Proton-dependent multidrug efflux systems. Microbiol Rev 1996; 60:575-608.
22. Mitchell BA, Brown MH, Skurray RA. QacA multidrug efflux pump from Staphylococcus aureus: comparative analysis of resistance to diamidines, biguanidines, and guanylhydrazones. Antimicrob Agents Chemother 1998; 42:475-7.
23. Schumacher MA, Miller MC, Grkovic S, Brown MH, Skurray RA, Brennan RG. Structural mechanisms of QacR induction and multidrug recognition. Science 2001; 294:2158-63.
24. Okusu H, Ma D, Nikaido H. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic- resistance (Mar) mutants. J Bacteriol 1996; 178:306-8.
25. Neyfakh AA, Borsch CM, Kaatz GW. Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrob Agents Chemother 1993; 37:128-9.
26. Truong-Bolduc QC, Zhang X, Hooper DC. Characterization of NorR protein, a multifunctional regulator of norA expression in Staphylococcus aureus. J Bacteriol 2003; 185:3127-38.
27. Ingavale SS, Van Wamel W, Cheung AL. Characterization of RAT, an autolysis regulator in Staphylococcus aureus. Mol Microbiol 2003; 48: 1451-66.
28. Luong TT, Newell SW, Lee CY. mgr, a novel global regulator in Staphylococcus aureus. J Bacteriol 2003; 185:3703-10.
29. Gill MJ, Brenwald NP, Wise R. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43:187-9.
30. Makino S, Asakura H, Obayashi T, Shirahata T, Ikeda T, Takeshi K. Molecular epidemiological study on tetracycline resistance R plasmids in enterohaemorrhagic Escherichia coli O157:H7. Epidemiol Infect 1999; 123: 25-30.
31. Hartman AB, Essiet II, Isenbarger DW, Lindler LE. Epidemiology of tetracycline resistance determinants in Shigella spp. and enteroinvasive Escherichia coli: characterization and dissemination of tet(A)-1. J Clin Microbiol 2003; 41:1023-32.
32. Lomovskaya O, Warren MS, Lee A, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001; 45:105-16.
33. Jalal S, Ciofu O, Hoiby N, Gotoh N, Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 2000; 44:710-2.
34. Ziha-Zarifi I, Llanes C, Köhler T, Pechère JC, Plesiat P. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother 1999; 43:287-91.
35. Mazzariol A, Zuliani J, Cornaglia G, Rossolini GM, Fontana R. AcrAB efflux system: expression and contribution to fluoroquinolone resistance in Klebsiella spp. Antimicrob Agents Chemother 2002; 46:3984-6.
36. Alekshun MN, Levy SB. The mar regulon: multiple resistance to antibiotics and other toxic chemicals. Trends Microbiol 1999; 7:410-3.
37. Oethinger M, Podglajen I, Kern WV, Levy SB. Overexpression of the marA or soxS regulatory gene in clinical topoisomerase mutants of Escherichia coli. Antimicrob Agents Chemother 1998; 42:2089-94.
38. Maneewannakul K, Levy SB. Identification of mar mutants among quinolone-resistant clinical isolates of Escherichia coli. Antimicrob Agents Chemother 1996; 40:1695-8.
39. Mazzariol A, Tokue Y, Kanegawa TM, Cornaglia G, Nikaido H. High-level fluoroquinolone-resistant clinical isolates of Escherichia coli over-produce multidrug efflux protein AcrA. Antimicrob Agents Chemother 2000; 44:3441-3.
40. Wang H, Dzink-Fox JL, Chen MJ, Levy SB. Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations. Antimicrob Agents Chemother 2001; 45: 1515-21.
41. Veal WL, Shafer WM. Identification of a cell envelope protein (MtrF) involved in hydrophobic antimicrobial resistance in Neisseria gonorrhoeae. J Antimicrob Chemother 2003; 51:27-37.
42. Zarantonelli L, Borthagaray G, Lee EH, Veal W, Shafer WM. Decreased susceptibility to azithromycin and erythromycin mediated by a novel mtr(R) promoter mutation in Neisseria gonorrhoeae. J Antimicrob Chemother 2001; 47:651-4.
43. Lin J, Michel LO, Zhang QJ. CmeABC functions as a multidrug efflux system in Campylobacter jejuni. Antimicrob Agents Chemother 2002; 46: 2124-31.
44. Pumbwe L, Randall LP, Woodward MJ, Piddock LJ. Expression of the efflux pump genes cmeB, cmeF and the porin gene porA in multiple-antibiotic-resistant Campylobacter jejuni. J Antimicrob Chemother 2004; 54:341-7.
45. Alonso A, Martinez JL. Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2000; 44:3079-86.
46. Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother 2001; 45: 3375-80.
47. Schmitz FJ, Hertel B, Hofmann B, et al. Relationship between mutations in the coding and promoter regions of the norA genes in 42 unrelated clinical isolates of Staphylococcus aureus and the MICs of norfloxacin for these strains. J Antimicrob Chemother 1998; 42:561-3.
48. Schmitz FJ, Fluit AC, Brisse S, Verhoef J, Kohrer K, Milatovk D. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS Immunol Med Microbiol 1999; 26:281-7.
49. Kaatz GW, Seo SM, O'Brien L, Wahiduzzaman M, Foster TJ. Evidence for the existence of a multidrug efflux transporter distinct from NorA in Staphylococcus aureus. Antimicrob Agents Chemother 2000; 44:1404-6.
50. Markham PN, Neyfakh AA. Inhibition of the multidrug transporter NorA prevents emergence of norfloxacin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1996; 40:2673-4.
51. Noguchi N, Hase M, Kitta M, Sasatsu M, Deguchi K, Kono M. Antiseptic susceptibility and distribution of antiseptic-resistance genes in methicillin-resistant Staphylococcus aureus. FEMS Microbiol Lett 1999; 172: 247-53.
52. Brenwald NP, Gill MJ, Wise R. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998; 42:2032-5.
53. Piddock LJV, Johnson MM, Simjee S, Pumbwe L. Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2002; 46:808-12.
54. Broskey J, Coleman K, Gwynn MN, et al. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae. J Antimicrob Chemother 2000; 45:95-9.
55. Singh KV, Weinstock GM, Murray BE. An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin. Antimicrob Agents Chemother 2002; 46:1845-50.
56. Lomovskaya O, Lewis K. emr, an Escherichia coli locus for multidrug resistance. Proc Natl Acad Sci USA 1992; 89:8938-42.
57. Edgar R, Bibi E. MdfA, an Escherichia coli multidrug resistance protein with an extraordinarily broad spectrum of drug recognition. J Bacteriol 1997; 179:2274-80.
58. Poole K, Krebes K, McNally C, Neshat S. Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J Bacteriol 1993; 175:7363-72.
59. Chuanchuen R, Beinlich K, Hoang TT, Becher A, Karkhoff-Schweizer RR, Schweizer HP. Cross-resistance between triclosan and antibiotics in Pseudomonas aeruginosa is mediated by multidrug efflux pumps: exposure of a susceptible mutant strain to triclosan selects nfxB mutants overexpressing MexCD-OprJ. Antimicrob Agents Chemother 2001; 45:428-32.
60. Köhler T, Michea-Hamzehpour M, Henze U, Gotoh N, Curty L, Pechère JC. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol 1997; 23: 345-54.
61. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44:3322-7.
62. Truong-Bolduc QC, Dunman PM, Strahilevitz J, Projan S, Hooper DC. MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus. J Bacteriol 2005; 187:2395:405.
63. Huang J, O'Toole PW, Shen W, et al. Novel chromosomally encoded multidrug efflux transporter MdeA in Staphylococcus aureus. Antimicrob Agents Chemother 2004; 48:909-17.
64. Narui K, Noguchi N, Wakasugi K, Sasatsu M. Cloning and characterization of a novel chromosomal drug efflux gene in S. aureus. Biol Pharm Bull 2002; 25:1533-6.
65. Lewis K, Hooper DC, Ouellette M. Multidrug resistance pumps provide broad defense. ASM News 1997; 63:605-10.